HER2 metastatic breast cancer

Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy...



The FDA ( Food and Drug Administration ) has granted accelerated approval to Ibrance ( Palbociclib ) to treat advanced...


T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab...


Prolonging first-line chemotherapy results with maintenance treatment may influence overall survival. In HER2-negative patients with locally recurrent/metastatic breast cancer, combining...


Combining Bevacizumab ( Avastin ) with first- or second-line chemotherapy in randomised phase III trials showed significantly improved progression-free survival...


Pfizer has announced that the randomized Phase 2 trial, PALOMA-1, of Palbociclib achieved its primary endpoint by demonstrating a statistically...


Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic...


Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the...


Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 ( known...


Data from a pooled analysis presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (...


Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people...


The College of American Pathologists ( CAP ) and the American Society of Clinical Oncology ( ASCO ) have issued...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to...


Pfizer has announced its investigational compound Palbociclib ( PD-0332991 ), an oral and selective inhibitor of cyclin-dependent kinases 4 and...


The FDA ( Food and Drug Administration ) has approved Kadcyla ( Trastuzumab Emtansine ), a new therapy for patients...


Halaven ( Eribulin mesylate ), a non-taxane, microtubule dynamics inhibitor with a novel mechanism of action, belongs to a class...


The results of a phase III study ( Study 301 ) of Eribulin mesylate ( Halaven ) versus Capecitabine (...


The FDA ( Food and Drug Administration ) has approved Pertuzumab injection ( Perjeta ) for use in combination with...